Buffered Lidocaine Syringes at Brooke Army Medical Center, JBSA Ft. Sam Houston, TX
Archived on July 9, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 11:00 AM CDT
- Posted
- June 10, 2026
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDepartment of the Army
Notice details
- Office
- US ARMY MEDICAL COMMAND.US ARMY HEALTH CONTRACTING ACTIVITY.W40M MRC0 WEST
- Place of performance
- DWG, Texas, 78234
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- W81K00-26-Q-A001
- Notice ID
- 73b2f5c7f73f48c3a4c40ea8daca601f
Description
Please complete the SF1449: Blocks 17 (to include the CAGE code and the Unique Entity ID Number) and 30 A - C.
Please provide a statement that the offeror will hold its quote firm for at least 90 days from the due date for receipt of quotes, subject to any changes that may occur as a result of discussions (if applicable).
Please complete the provisions, as listed in the solicitation. Alternately, complete all provisions in System for Award Management (SAM) and provide confirmation of completion and accuracy with offer. Potential contractors must be registered in SAM to be eligible for award. The SAM website is http://www.sam.gov.
Quotes are due by no later than (NLT) 11:00 AM/CT on 24 June 2026. Quotes shall be submitted via email to patrick.a.thielemann.civ@health.mil and christopher.a.gregory11.civ@health.mil. Quotes received after the deadline will be considered untimely and will not be eligible for award. Questions are by NLT 11:00 AM/CT on 15 June 2026. All questions must be
submitted in writing to patrick.a.thielemann.civ@health.mil and christopher.a.gregory11.civ@health.mil. Electronic submissions with files larger than 20MB will need to be submitted in separate emails. All emails, regardless of the size, need to be received by the Government server, by the stated date and time. It is the offeror's responsibility to ensure the Government receives the entire quote.
Factor 1. Compliance with specification: The contractor must provide proof of compliance
federal regulations, as outlined by the FDA, and state regulations in the production and/or
distribution of the required producsts.
Factor 2. Price: Offeror shall complete the pricing for each of the contract line items (CLINS)
under the Continuation of Supplies or Services and Prices/Costs or provide a separate
document with the pricing for each CLIN.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Lifecycle
- 3Version 3Sources SoughtArchived
Buffered Lidocaine Syringes at Brooke Army Medical Center, JBSA Ft. Sam Houston, TX
- 4Version 4Combined Synopsis/SolicitationArchived
Type changed from Sources Sought to Combined Synopsis/Solicitation
Buffered Lidocaine Syringes at Brooke Army Medical Center, JBSA Ft. Sam Houston, TX
- 6Version 6Combined Synopsis/SolicitationArchivedCurrent
Buffered Lidocaine Syringes at Brooke Army Medical Center, JBSA Ft. Sam Houston, TX
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer. | - | Awarded | Open |
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice. | - | Special Notice | 10/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 10/26/2026 |
Herbicide/ Pesticide Purchase Synopsis See Attached for Details | - | Pre-Solicitation | 09/22/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 08/27/2026 |
Additional Details
Solicitation Number
W81K00-26-Q-A001
Archive Date
Jul 9, 2026
Office Address
JBSA FT SAM HOUSTON, TX, 78234-4504